

A signed statement by the applicant that the research work under reference has not been given any award. The applicant should also indicate the extent of the contribution of the others associated with the research and he/she should clearly acknowledge his/her achievements (Max: 500 KB)

I certify that research work under reference (1-41 mentioned below) has not been given any award.

1. Sadhu S, Dalal R, Dandotia J, Binayke A, Vinayak KV, Shakti K, Singh V, Goswami S, Tripathy MR, Rizvi ZA, **Awasthi A**. **IL-9 exacerbates SARS-CoV2 infection and associated airway inflammation**, **Nature Communication 2023**, Manuscript ID: NCOMMS-22-28241C.

Author Contribution:

Conceived, designed, and supervised the study: **A.A.** Designed and performed the experiments: S.S, R.D and JD Animal experiments: S.S. and R.D. FACS: S.S, R.D & ZAR. qPCR: V.D, V.S, SKG. and M.R.T. ELISA: J.D. Metagenomics analysis: S.S, & S.K. Analyzed the data: Z.A.R., R.D., S.S. Contributed reagents/materials/analysis tools: A.A. Wrote the manuscript: S.S. and **A.A.**

2. Rizvi ZA, Dalal R, Sadhu S, Kumar Y, Kumar S, Gupta SK, Tripathy MR, Rathore DK, **Awasthi A**. **High salt diet mediates interplay between NK cells and gut microbiota to induce potent tumor immunity**. **Science Advances 2021**, 7(37):eabg5016. doi: 10.1126/sciadv.abg5016.

Author contributions

Conceived, designed, and supervised the study: **A.A.** Designed and performed the experiments: Z.A.R. and R.D. Animal experiments: Z.A.R. and R.D. FACS: Z.A.R., R.D., and D.K.R. Metabolomics: Z.A.R., Y.K., and S.K.G. qPCR: Z.A.R. and M.R.T. ELISA: Z.A.R. Metagenomics analysis: S.K. Analyzed the data: Z.A.R., R.D., S.S., and D.R. Contributed reagents/materials/analysis tools: A.A. Wrote the manuscript: Z.A.R. and **A.A.**

3. Rizvi ZA, Dalal R, Sadhu S, Binayke A, Dandotiya J, Kumar Y, Shrivastava T, Gupta SK, Aggarwal S, Tripathy M, Rathore DK, Yadav AK, Medigeshe GR, Pandey A, Samal S, Asthana A, **Awasthi A**. Golden syrian hamster as a model to study cardiovascular complications associated with SARS-CoV2 infection. **eLife 2022**, Jan 11;11:e73522. doi: 10.7554/eLife.73522.
4. Thiruvengadam R, **Awasthi A**, Medigeshe GR, Bhattacharya S, Mani S, Sivasubbu S, Shrivastava S, Samal S, Murugesan DR, Desiraju BK, Kshetrapal P, Pandey R, Scaria V, Malik PK, Taneja J, Binayke A, Vohra T, Zaheer A, Rathore D, Khan NA, Shaman H, Ahmed S, Kumar R, Deshpande S, Subramani C, Wadhwa N, Gupta N, Pandey AK, Bhattacharya J, Agrawal A, Vrati S, Bhatnagar S, Garg PK. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. **Lancet Infectious Disease 2021**, Nov 25:S1473-3099(21)00680-0 [https://doi.org/10.1016/S1473-3099\(21\)00680-0](https://doi.org/10.1016/S1473-3099(21)00680-0)
5. Roy S, Asthana A, Goyal R, Yadav AK, **Awasthi A**. Proteome analysis revealed the essential functions of PP2A in the induction of Th9 cells. **Scientific Reports 2020**, 10:10992. doi: 10.1038/s41598-020-67845-2.
6. Samal S, Shrivastava T, Sonkusre P, Rizvi ZA, Kumar R, Ahmed S, Bansal M, Chauhan K, Pokhrel S, Tambare P, **Awasthi A**. Influenza A H1N1 M2e soluble immunogen derived from mammalian expression system form higher order oligomers and show enhanced immunogenicity in vivo. **J Biol Chem 2020**, jbc.RA120.013233. doi: 10.1074/jbc.RA120.013233.

7. Zhang H, Madi A, Yosef N, Chihara N, **Awasthi A**, Pot C, Lambden C, Srivastava A, Burkett PR, Nyman J, Christian E, Etminan Y, Lee A, Stroh H, Xia J, Karwacz K, Thakore PI, Acharya N, Schnell A, Wang W, Apetoh L, Rozenblatt-Rosen O, Anderson AC, Regev A, Kuchroo VK. IL-27 driven transcriptional network identifies regulators of IL-10 expression across T helper cell subset. **Cell Reps** **2020**, 33:108433. doi: 10.1016/j.celrep.2020.108433.
8. Rampal R, Saurabh Kedia, **Awasthi A**, Ahuja A. Retinoic acid is elevated in the mucosa of patients with active ulcerative colitis and displays a pro-inflammatory role by augmenting IL-17 and IFN γ production. **Inflammatory Bowel Diseases** **2021**, 27:74-83. doi: 10.1093/ibd/izaa121
9. Mittal L, Srivastava M, Kumari A, Tonk RK, **Awasthi A***, Asthana S. The interplay among structural stability, plasticity and energetics is determined by conformational attuning of flexible loops of PD-1. **Journal of Chemical Information and Modelling** **2021**, 61:358-384. doi: 10.1021/acs.jcim.0c01080.
*Co-corresponding author
10. Samal S, Shrivastava T, Sonkusre P, Rizvi ZA, Kumar R, Ahmed S, Bansal M, Chauhan K, Pokhrel S, Tambare P, **Awasthi A**. Influenza A H1N1 M2e soluble immunogen derived from mammalian expression system form higher order oligomers and show enhanced immunogenicity in vivo. **J Biol Chem** **2020**, jbc.RA120.013233. doi: 10.1074/jbc.RA120.013233.
11. Roy S, Rizvi ZA, Clarke A, Macdonald F, Pandey A, Zaiss D, Dr. Simon KA, **Awasthi A**. EGFR-HIF1 α signaling positively regulates the differentiation of IL-9 producing T helper cells. **Nature Communication** **2021**, 12(1):3182. doi: 10.1038/s41467-021-23042-x
12. Sadhu S, Rizvi ZA, Pandey RP, Dalal R, Rathore DK, Kumar B, Pandey M, Kumar Y, Goel R, Maiti TK, Tiwari A, Pandey AK, **Awasthi A**. EGFR-HIF1 α axis is essential for the intracellular survival of *Salmonella*. **Front Immunol.** **2021**, 12:648710. doi: 10.3389/fimmu.2021.648710.
13. Vishwakarma P, Yadav N, Rizvi ZA, Khan NA, Chiranjivi A, Shrivastava T, Bansal M, Dwivedi P, Kumar R, **Awasthi A**, Ahmed S, Samal S. Characterization of SARS-CoV2 Spike Protein Synthetic Peptides as potential targets for vaccine and therapeutics. **Front Immunol.** **2021**, 12:613045. doi: 10.3389/fimmu.2021.613045.
14. Chauhan S, Rathore DK, Lacroix-Desmazes S, Gupta N, **Awasthi A**, Vrati S, Kalia M. Japanese encephalitis virus infected human monocyte-derived dendritic cells activate a transcriptional network leading to an antiviral inflammatory response. **Front Immunol.** **2021**, 12:638694. doi: 10.3389/fimmu.2021.638694.
15. Ganneru B, Jogdand H, Dharam VK, Mulugu N, Prasad B S, Srinivas VK, Ella K, Ravikrishnan R, **Awasthi A**, Jose J, Rao P, Kumar D, Abraham P, Yadav P, Sapkal G, Shete A, Deshpande GR, Mohandas S, Basu A, Gupta N, Bhargava B, Mohan K, Ella R. Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion Inactivated SARS-CoV-2 Vaccine - BBV152. **iScience** **2021**, 24 (4):102298. doi: 10.1016/j.isci.2021.102298
16. Lin X, Gaudino S, Roy S, Castillo P, Elsegeiny W, Wakabayashi N, Oury TD, Pociask D, Chen K, **Awasthi A**, Kolls JK and Kumar P. Nrf2 differentially regulates IL-22 and IL-17A response in CD4 $^{+}$ T cells through Ahr and SOD3 axis. **Journal of Immunology** **2021**, 206 (7); 1540-1548; doi: 10.4049/jimmunol.1900656.
17. Yadav N, Vishwakarma P, Khatri R, Siddiqui G, **Awasthi A**, Ahmed S, Samal S. Comparative Immunogenicity analysis of Intra dermal and Intra muscular administration of SARS-CoV2 RBD epitope peptide-based Immunogen. **Microbes and Infection** **2021**, 23(4-5):104843. doi: 10.1016/j.micinf.2021.104843.

18. Shrivastava T, Singh B, Rizvi ZA, Verma R, Goswami S, Vishwakarma P, Jakhar K, Sonar S, Mani S, Bhattacharyya S, **Awasthi A**, Surjit M. Comparative immunomodulatory evaluation of the receptor binding domain of SARS CoV-2 spike protein; a potential vaccine candidate, imparts potent humoral and Th1 type of immune response in a mouse model. **Front Immunol.** **2021**, 12:641447. doi: 10.3389/fimmu.2021.641447.
19. Mittal L, Tonk RK, **Awasthi A**, Asthana S. Targeting cryptic-orthosteric site of PD-L1 for inhibitor identification using structure-guided approach. **Arch Biochem Biophys.** **2021**, 713:109059. doi: 10.1016/j.abb.2021.109059
20. Rizvi ZA, Tripathy MR, Sharma N, Goswami S, Srikanth N, Sastry JLN, Mani S, Surjit M, **Awasthi A***, Dikshit M. Effect of prophylactic use of intra-nasal oil formulation in the hamster model of Covid19. **Frontiers in Pharmacology** **2021**, Oct 14;12:746729. doi: 10.3389/fphar.2021.746729. ***Co-corresponding author**
21. Thiruvengadam R, Binayke A, **Awasthi A**. SARS-CoV-2 delta variant – a persistent threat to the effectiveness of vaccines. **Lancet Infectious Disease** **2022**, **22(3)**:301-302. doi: 10.1016/S1473-3099(21)00697-6.
22. Suri C, **Awasthi A***, Asthana S. RoR α agonist, inverse agonists and allosteric inhibitors- a crystallographic landscape. **Drug Discovery Today** **2022**, Nov 24:S1359-6446(21)00503-1. doi: 10.1016/j.drudis.2021.11.022. ***Co-corresponding author**
23. Thiruvengadam R, **Awasthi A**, Bhatnagar S, Garg PK. Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India - Authors' reply. **Lancet Infectious Disease** **2022**, **22(4)**:447. doi: 10.1016/S1473-3099(22)00120-7.
24. Hingankar N, Deshpande S, Das P, Rizvi ZA, Burns A, Barman S, Zhao F, Ansari MY, Mukherjee S, Torres JL, Chattopadhyay S, Mehdi F, Sutar J, Rathore DK, Pargai K, Singh J, Sonar S, Jakhar K, Bhattacharyya S, Mani S, Singh S, Dandotiya J, Kshetrapal P, Thiruvengadam R, Batra G, Medigeshe G, Ward AB, Bhatnagar S, **Awasthi A**, Sok D, Bhattacharya J. A combination of potentially neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 delta variant. **2022, Plos Pathogens.** doi.org/10.1371/journal.ppat.1010465.
25. Mittal L, Tonk R, **Awasthi A**, Asthana S. Traversing through the dynamic protein-protein interaction landscape and conformational plasticity of PD-1 for small molecule discovery. **Medicinal Chemistry**, **2022**. doi: 10.1021/acs.jmedchem.2c00176
26. Khatri R, Parray HA, Agrahari AK, Rizvi ZA, Kaul R, Raj S, Asthana S, Mani S, Sweet Samal, **Awasthi A**, Ahmed S. Designing and characterization of a SARS-CoV-2 immunogen with receptor binding motif grafted on a protein scaffold: An epitope-focused vaccine approach. **International Journal of Biological Macromolecules**. **2022**. 22:S0141-8130(22)00861-3. DOI: 10.1016/j.ijbiomac.2022.04.148.
27. Kumar CS, Singh B, Rizvi ZA, Parray HA, Verma JK, Ghosh S, Mukhopadhyay A, **Awasthi A**, Shrivastava T, Banerjee M. Virus-like particles of SARS-CoV-2 as virus surrogates: morphology, immunogenicity, and internalization in neuronal cells. **2022, ACS Infectious Diseases**, doi.org/10.1021/acsinfecdis.2c00217.
28. Rizvi ZA, Babele P, Sadhu S, Madan U, Tripathy MR, Goswami S, Shailendra Mani, Kumar S, Awasthi A, Dikshit M. Prophylactic treatment of *Glycyrrhiza glabra* mitigates COVID-19 pathology through inhibition of pro-inflammatory cytokines in the hamster model and NETosis. **Frontiers in Immunology**, **2022**. doi.org/10.3389/fimmu.2022.945583.

29. Binayke A, Zaheer A, Dandotiya Y, Kumar Y, Mani S, Madan U, Tripathy MR, Gupta SK, Shrivastava T, Rathore DK, Pandey AK, Awasthi A. Proinflammatory innate cytokines and metabolomic signatures predict T cell response in active COVID-19. **Vaccine** 2022. doi.org/ 10.3390/vaccines10101762.
30. Thuluva S, Paradkar V, Turaga K, Gunneri SR, Yerroju V, Mogulla R, Suneetha PV, Kyasani M, Manoharan SK, Adabala S, Javvadi AS, Medigeshi G, Singh J, Shaman H, Binayke A, Zaheer A, **Awasthi A**, Singh C, Rao AV, Basu I, Khobragade AK, Pandey AK. Immunogenic superiority and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase III, single blind, multicenter, randomized clinical trial. **medRxiv**, doi: <https://doi.org/10.1101/2022.03.20.22271891>. under advanced revision **E-Biomedicine**.
31. Rizvi ZA, Sadhu S, Dandotiya J, Sharma P, Singh V, Das V, Kumar R, Samal S, Kalia M, **Awasthi A**. SARS-CoV-2 and its variants, but not Omicron, induce thymic atrophy and impaired T cell development. 2022, **submitted**. <https://doi.org/10.1101/2022.04.07.487556>.
32. Roy SS, Sharma S, Rizvi ZA, Sinha D, Gupta D, Rophina M, Sehgal P, Maiti S, Scaria V, Sivasubbu S, **Awasthi A**, Harshan KH, Jain S, Chowdhury S. Anti-COVID-19 Activity of FDA Approved Drug through RNA G-quadruplex Binding. **Submitted biorxiv**. <https://doi.org/10.1101/2022.05.31.493843>.
33. Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, Vijay Yerroju, Rammohan Reddy Mogulla, Pothakamuri Venkata Suneetha, Kishore Turaga, Mahesh Kyasani, Senthil Kumar Manoharan, Srikanth Adabala, Aditya Sri Javvadi, Guruprasad Medigeshi, Janmejaya Singh, Heena Shaman, Akshay Binayke, Aymaan Zaheer, **Awasthi A**, Manish Narang, Pradeep Nanjappa, Niranjana Mahantshetti, Bishan Swarup Garg, Anil Kumar Pandey. Safety, tolerability and immunogenicity of Biological E's CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study. **Vaccine** 2022, doi.org/10.1016/j.vaccine.2022.10.045.
34. Ramachandran T, Rizvi ZA, Sreevatsan R, Deepika Rathna Murugesan, Mudita Gosain, Dandotiya J, **Ayushi A**, Sweetie S, Pandey AK, Nitya Wadhwa, Shinjini Bhatnagar, Amit Awasthi, Pramod Kumar Garg. Clinical and experimental evidence suggest omicron SARS-CoV-2 is inherently less pathogenic than delta independent of previous immunity. **Submitted, Research Square** 2022. DOI: <https://doi.org/10.21203/rs.3.rs-2258374/v1>.
35. Thuluva S, Paradkar V, Gunneri S, Yerroju V, Mogulla R, Pothakamuri SV, Turaga K, Kyasani M, Manoharan S, Adabala S, Javvadi AS, Medigeshi GR, Singh J, Shaman H, Binayke A, Aymaan Z, **Awasthi A**, Narang M, Pradeep N, Mahantshetti N, Garg BS, Ravi M. Safety, tolerability and immunogenicity of Biological Es CORBEVAX vaccine in children and adolescents: A Prospective, Randomised, Double-blind, Placebo controlled, Phase-2/3 Study. **Vaccine** 2022, doi: <https://doi.org/10.1101/2022.04.20.22274076>.
36. Parray HA, Narayanan N, Garg S, Rizvi ZA, Shrivastava T, Kushwaha S, Singh J, Murugavelu P, Anbalagan A, Mehdi F, Raj N, Singh S, Dandotiya J, Lukose A, Jamwal D, Kumar S, Chiranjivi A, Dhyani S, Mishra N, Jakhar K, Sonar S, Panchal AK, Tripathy MR, Ahamed S, Samal S, Mani S, Bhattacharyya S, Das S, Sinha S, Luthra L, Batra G, Sehgal D, Medigeshi G, Sharma C, **Awasthi A***, Garg PK, Nair DT, Kumar R. A broadly neutralising monoclonal antibody overcomes the mutational landscape of emerging SARS-CoV2 variant of concerns. **(*Co-corresponding author). PLOS pathogen** 2022. doi:10.21203/rs.3.rs-1431974/v1.
37. Roy, S.S., Sharma, S., Rizvi, Z.A., Sinha, D., Gupta, D., Rophina, M., Sehgal, P., Sadhu, S., Tripathy, M.R., Samal, S. and Maiti, S., 2023. G4-binding drugs, chlorpromazine and prochlorperazine, repurposed against COVID-19 infection in hamsters. **Frontiers in molecular biosciences**, 2023 10, p.1133123.
38. Rizvi, Z.A., Babele, P., Madan, U., Sadhu, S., Tripathy, M.R., Goswami, S., Mani, S., Dikshit, M. and Awasthi, A., 2023. Pharmacological potential of Withania somnifera (L.) Dunal and Tinospora cordifolia

(Willd.) Miers on the experimental models of COVID-19, T cell differentiation, and neutrophil functions. *Frontiers in Immunology* **2023**. doi: 10.3389/fimmu.2023.1138215.

39. Khatri, Ritika, Gazala Siddqui, Srikanth Sadhu, Vikas Maithil, Preeti Vishwakarma, Bharat Lohiya, Abhishek Goswami, Shubbir Ahmed, Amit Awasthi, and Sweetly Samal. "Intrinsic D614G and P681R/H mutations in SARS-CoV-2 VoCs Alpha, Delta, Omicron and viruses with D614G plus key signature mutations in spike protein alters fusogenicity and infectivity. *Medical Microbiology and Immunology* (2023): 1-20. DOI: 10.1007/s00430-022-00760-7.
40. Ansari S, Gupta N , Verma R , Singh O , Gupta J , Kumar a ,Yadav M , Binayke A ,Tiwari M, Periwal N, Sood V , Mani S, **Awasthi A** , Shalimar ,Nayak B , Ranjith CT, Surjit M.K, Antiviral activity of the human endogenous retrovirus-R envelope protein against SARS-CoV-2. **Accepted in EMBO reports 2023**, Ref ID- EMBOR-2022-55900V3.
41. Rizvi ZA*, Sharma K, Srikanth S, Dandotiya J, Khatri R, Singh V, Adhikari N, Das V, Mani S, Samal S, **Awasthi A***. Omicron sub-lineage BA.5 infection causes attenuated pathology and results in robust protection in Omicron-recovered hACE2 transgenic mice. **Accepted and ahead for publication Communications Biology,2023**. (ISSN 2399-3642).



Dr. Amit Awasthi,
Senir Professor,
Translational Health Science & Technology Institute,
Faridabad, Haryana